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OBJECTIVE — Glycated albumin (GA) relative to A1C is a useful marker of short-term
glycemic control. We investigated whether endogenous insulin secretion in type 2 diabetes has
different effects on GA and A1C levels.
RESEARCH DESIGN AND METHODS — A1C, GA, and GA-to-A1C ratio were com-
pared in 202 type 2 diabetic patients by type of treatment. Effect of -cell function determined
by homeostasis model assessment (HOMA-%) on GA-to-A1C ratio was examined. In addition,
GA-to-A1C ratio was compared between type 2 diabetic patients and 16 patients with type 1
diabetes.
RESULTS — In type 2 diabetic patients, GA-to-A1C ratio was signiﬁcantly higher in those
treated with insulin than in those treated with diet or oral hypoglycemic agents. HOMA-%
showed a signiﬁcant inverse correlation with GA-to-A1C ratio. This ratio was higher in type 1
diabetic patients than in type 2 diabetic patients.
CONCLUSIONS — In diabetic patients with decreased insulin secretion, serum GA levels
are higher relative to A1C.
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A
1C is used clinically as a parameter
of glycemic control state over the
previous 1–2 months (1). Measure-
ment of A1C may be affected by condi-
tions that shorten the life span of
erythrocytes and variant hemoglobin,
causing erroneous values for glycemic
control (2). As other markers of glycemic
control, serum glycated albumin (GA)
and serum fructosamine are useful to re-
ﬂect shorter-term glycemic control (2
weeks) (3). However, these glycated pro-
teins do not accurately reﬂect glycemic
control in disorders of albumin metabo-
lism.
Recently, GA-to-A1C ratio has been
reported to be signiﬁcantly higher in pa-
tients with type 1 diabetes than in those
with type 2 diabetes, indicating that se-
rum GA is a more sensitive marker than
A1C for glucose excursions (4). The un-
derlying mechanism may involve marked
ﬂuctuation in plasma glucose levels asso-
ciated with decreased insulin secretion in
type 1 diabetic patients (4). The present
study investigated whether endogenous
insulin secretion has different effects on
GA and A1C levels.
RESEARCH DESIGN AND
METHODS— This study enrolled
202outpatientswithtype2diabetes(119
male subjects and 83 female subjects) as
diagnosed based on American Diabetes
Association criteria (5). Exclusion criteria
were variation 0.5% in A1C values dur-
ing the previous 3 months, chronic liver
disease,renaldisease,thyroiddisorder,ane-
mia, and corticosteroid treatment. The
meanagewas64.210.7years,BMIwas
24.2  3.7 kg/m
2, and duration of diabe-
tes was 13.1  9.7 years. Treatment in-
volved diet alone in 41 patients, oral
hypoglycemic agents (OHAs) in 112 pa-
tients, and insulin in 49 patients. Fasting
C-peptide and fasting plasma glucose
were measured, and -cell function was
quantiﬁed using homeostasis model as-
sessment (HOMA-%) (6). In addition,
GA-to-A1C ratio was compared between
the 202 type 2 diabetic patients and 16
type 1 diabetic patients (8 male subjects
and 8 female subjects, aged 60.6  14.0
years, BMI 22.7  2.8 kg/m
2, and all re-
ceiving insulin therapy).
Serum fasting C-peptide was deter-
mined by chemiluminescent enzyme-
immunoassay (Fujirebio, Tokyo, Japan).
A1C was measured with an ADAMS-A1C
HA-8160 automatic A1C analyzer
(Arkray, Kyoto, Japan) based on high-
performance liquid chromatography. Se-
rum GA was determined by a Hitachi
7600 autoanalyzer (Hitachi Instruments
Service, Tokyo, Japan) based on an enzy-
matic method using an albumin-speciﬁc
proteinase, ketoamine oxidase, and an al-
bumin assay reagent (Lucica GA-L; Asahi
Kasei Pharma, Tokyo, Japan).
RESULTS— We compared A1C, GA,
and GA-to-A1C ratio in 202 type 2 dia-
beticpatientswithtypeoftreatment.Both
A1C and GA were signiﬁcantly higher
in 49 patients treated with insulin and in
112 patients treated with OHAs than in
41 patients treated with diet alone (data
notshown).Bycontrast,GA-to-A1Cratio
did not differ between patients treated
with OHAs (2.86  0.34) and those
treatedwithdietalone(2.790.28),and
it was signiﬁcantly higher in patients
treatedwithinsulin(3.000.37)thanin
those treated with OHAs (P  0.05) and
those treated with diet alone (P  0.01).
In multivariate analysis performed with
sex, age, BMI, and insulin therapy as ex-
planatory variables for GA-to-A1C ratio
in type 2 diabetic patients, BMI, age, and
insulin treatment were identiﬁed as inde-
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shown). GA-to-A1C ratio was signiﬁ-
cantly higher in 16 type 1 diabetic pa-
tients (3.15  0.26) than in 202 type 2
diabetic patients (2.87  0.36) (P 
0.001) but showed no signiﬁcant differ-
ence compared with 49 type 2 diabetic
patients treated with insulin. By power
analyses, each number of patients was
found statistically adequate to make the
conclusions when the analytical power
was set at 80%.
HOMA-% was signiﬁcantly lower in
type 2 diabetic patients treated with insu-
lin than in those treated with diet alone
and those treated with OHAs (Fig. 1A). A
signiﬁcant inverse correlation was ob-
served between GA-to-A1C ratio and
HOMA-% (Fig. 1B). Stepwise multivar-
iate analysis including HOMA-%, sex,
age, and BMI to identify explanatory vari-
ables for GA-to-A1C ratio showed that
BMI ( 0.203, F  9.6, P  0.015),
age (0.215, F  8.2, P  0.006), and
HOMA-% ( 0.237, F  6.4, P 
0.020) were found to be independent ex-
planatory variables.
CONCLUSIONS — Our ﬁndings
suggest that decreased endogenous insu-
lin secretion is involved in elevated GA-
to-A1C ratios. Yoshiuchi et al. (4)
reported that in type 1 diabetic patients,
glucose excursions or maximum glucose
levels based on diurnal plasma glucose
variations inﬂuence GA-to-A1C ratios. In
addition,GA-to-A1Cratioin158subjects
with normal glucose tolerance was
2.73  0.22 in our previous study (7),
signiﬁcantlylowerthanthatin202type2
diabetic patients in the present study. To-
gether with these ﬁndings, it is suggested
that decreased insulin secretion may in-
crease the GA-to-A1C ratio by causing
marked glucose excursions.
The reasons why serum GA reﬂects
postprandial hyperglycemia better than
A1C are unknown. The shortened life
span of erythrocytes in patients with dia-
betes and poor glucose control (8), lag-
ging GLUT1-mediated glucose uptake by
erythrocytesresultinginarelativelylower
degree of rise in A1C (9), different glyca-
tionratesbetweenalbuminandhemoglo-
bin (10), and the direct effect of insulin
andOHAsonserumalbuminmetabolism
(11) may be involved.
In the present study, BMI was an in-
dependent negative risk for GA-to-A1C
ratio, as we previously reported (7,12),
and was signiﬁcantly lower in type 2 dia-
betic patients treated with insulin and
type 1 diabetic patients than in type 2 di-
abetic patients treated with OHA or diet
alone. Thus, elevated GA-to-A1C ratio in
type 2 diabetic patients treated with insu-
lin and type 1 diabetic patients may be
caused by a lower BMI. However, adjust-
ment of GA-to-A1C ratio by BMI gave the
same conclusions (data not shown).
In the Diabetes Control and Compli-
cations Trial (DCCT), type 1 diabetic pa-
tients treated with intensive insulin
therapy had a markedly reduced preva-
lence of diabetic retinopathy and macro-
vascular complications compared with
those who had the same A1C levels
treated with conventional insulin therapy
(13).Thereasonproposedwasthatinten-
sive insulin therapy decreased glycemic
excursions thus emphasizing the need to
reduce glucose ﬂuctuations. If serum GA
levels had been measured in that study,
the relationship between serum GA levels
and the diabetes complications in inten-
sive versus conventional insulin therapy
would have been an interesting observa-
tion.
Postprandial hyperglycemia report-
edly increases the prevalence of cardio-
vascular diseases (14). If serum GA is
higher relative to A1C in the state of post-
prandial hyperglycemia, serum GA may
offer a better surrogate marker of cardio-
vascular risk. Along this line, it has re-
cently been reported that serum GA was
signiﬁcantlyelevatedinpatientswithcor-
onary artery stenosis (15).
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